Ulrich Mrowietz

Ulrich Mrowietz's AcademicInfluence.com Rankings

Ulrich Mrowietz

Biology

#11633

World Rank

#15042

Historical Rank

Cell Biology

#597

World Rank

#610

Historical Rank

Genetics

#1263

World Rank

#1365

Historical Rank

Molecular Biology

#1813

World Rank

#1842

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Ulrich Mrowietz Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ulrich Mrowietz's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Definition of treatment goals for moderate to severe psoriasis: a European consensus (2010) (729)
European S3‐Guidelines on the systemic treatment of psoriasis vulgaris (2009) (668)
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity (2012) (555)
Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci (2016) (549)
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease (2003) (441)
Quality of life of patients with keloid and hypertrophic scarring (2006) (429)
Identification of fifteen new psoriasis susceptibility loci highlights the role of innate immunity (2012) (397)
European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC (2015) (381)
Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa (2012) (366)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) (2015) (359)
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2 (2010) (343)
European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey (2006) (317)
Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation (2010) (314)
S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update (2012) (259)
Activation of the Aryl Hydrocarbon Receptor Dampens the Severity of Inflammatory Skin Conditions (2014) (253)
Dimethylfumarate is a potent inducer of apoptosis in human T cells. (2003) (242)
Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. (2015) (240)
Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. (2010) (235)
Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation (2015) (229)
Oxidative stress in the pathogenesis of psoriasis. (2009) (225)
Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants (2016) (219)
Dimethylfumarate for psoriasis: more than a dietary curiosity. (2005) (213)
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin‐17 inhibitors and their practical management (2017) (207)
European consensus statement on phenotypes of pustular psoriasis (2016) (200)
Expression and function of adenosine receptors in human dendritic cells (2001) (195)
The impact of treatment with tumour necrosis factor‐α antagonists on the course of chronic viral infections: a review of the literature (2008) (176)
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). (2015) (168)
Keloid scarring: bench and bedside (2009) (160)
Adipokines and psoriasis (2011) (157)
Increased expression of Wnt5a in psoriatic plaques. (2007) (157)
A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. (2002) (157)
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study) (2018) (155)
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice (1999) (152)
Genome-wide Comparative Analysis of Atopic Dermatitis and Psoriasis Gives Insight into Opposing Genetic Mechanisms (2015) (144)
Efficacy and safety of fumaric acid esters in the long‐term treatment of psoriasis – A retrospective study (FUTURE) (2009) (141)
Psoriasis: rationale for targeting interleukin‐17 (2012) (138)
Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. (2012) (132)
Clinical and genetic differences between pustular psoriasis subtypes (2018) (129)
A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasis (2014) (126)
ω-3 Fatty acid–based lipid infusion in patients with chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, multicenter trial (1998) (125)
The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients (2006) (125)
Genome-wide meta-analysis of Psoriatic Arthritis Identifies Susceptibility Locus at REL (2011) (120)
European S3‐Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC (2017) (120)
Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine--preparation of S-substituted thiosuccinic acid esters. (2007) (119)
Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest (2015) (117)
A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases (2015) (117)
Inhibition of dendritic cell differentiation by fumaric acid esters. (2001) (116)
S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment (2018) (111)
German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version) (2007) (109)
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. (2012) (109)
Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate‐to‐severe chronic plaque psoriasis: a randomized, double‐blind, Fumaderm®‐ and placebo‐controlled trial (BRIDGE) (2017) (108)
Genetic Susceptibility to Keloid Disease and Hypertrophic Scarring: Transforming Growth Factor &bgr;1 Common Polymorphisms and Plasma Levels (2003) (106)
Short‐ and long‐term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data (2017) (105)
Fumaric acid esters. (2008) (104)
German S3-guidelines on the treatment of psoriasis vulgaris (short version) (2012) (100)
Smoking and Alcohol Intake in Severely Affected Patients with Psoriasis in Germany (2009) (98)
Evidence‐based (S3) guidelines for the treatment of psoriasis vulgaris (2007) (94)
Leptin, adiponectin, visfatin and retinol‐binding protein‐4 – mediators of comorbidities in patients with psoriasis? (2012) (92)
Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study. (1992) (91)
Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars. (2005) (90)
S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011 (2011) (90)
An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2017) (89)
A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses (2003) (86)
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations (2020) (81)
German psoriasis registry PsoBest: objectives, methodology and baseline data (2014) (79)
Dimethylfumarate inhibits nuclear binding of nuclear factor κB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein β in activated human T cells (2007) (76)
Pruritus and quality of life in moderate‐to‐severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study (2015) (75)
Safety of Systemic Agents for the Treatment of Pediatric Psoriasis (2017) (75)
Psoriasis--new insights into pathogenesis and treatment. (2009) (74)
Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS) (2004) (72)
Psoriasis: to treat or to manage? (2014) (72)
Ustekinumab in the treatment of palmoplantar pustulosis (2010) (72)
Clinical use of dimethyl fumarate in moderate‐to‐severe plaque‐type psoriasis: a European expert consensus (2018) (71)
The Pharmacokinetics of Fumaric Acid Esters Reveal Their In Vivo Effects. (2018) (70)
Update on the use of ciclosporin in immune‐mediated dermatoses (2006) (69)
Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner. (2001) (69)
Secukinumab improves hand, foot and nail lesions in moderate‐to‐severe plaque psoriasis: subanalysis of a randomized, double‐blind, placebo‐controlled, regimen‐finding phase 2 trial (2014) (69)
Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome. (2010) (68)
Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. (2009) (68)
Non‐adherence and measures to improve adherence in the topical treatment of psoriasis (2014) (68)
Therapy of psoriasis in childhood and adolescence ‐ a German expert consensus (2011) (68)
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32‐week results from the randomized placebo‐controlled TRANSFIGURE trial (2019) (68)
Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients (2010) (67)
miR-146b Probably Assists miRNA-146a in the Suppression of Keratinocyte Proliferation and Inflammatory Responses in Psoriasis. (2017) (65)
Treatment of psoriasis with fumaric acid esters (Fumaderm®) (2007) (64)
Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: Results of a multicenter study (1995) (64)
Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis (2015) (63)
Management of palmoplantar pustulosis: do we need to change? (2011) (63)
Topical corticosteroids in psoriasis: strategies for improving safety (2010) (62)
Secukinumab for moderate‐to‐severe palmoplantar pustular psoriasis: Results of the 2PRECISE study (2019) (61)
TNF‐α: a treatment target or cause of sarcoidosis? (2015) (61)
Decreased expression of inhibitory SMAD6 and SMAD7 in keloid scarring. (2006) (60)
Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: A randomized comparison of efficacy and safety in subjects with scalp psoriasis (2005) (60)
Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice (2019) (59)
Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. (1998) (57)
Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? (2013) (55)
Treatment goals in psoriasis (2007) (54)
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis. (2016) (54)
Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures (2015) (53)
Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study (2017) (53)
Detection of fumarate–glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism (2013) (53)
Implementing treatment goals for successful long‐term management of psoriasis (2012) (53)
Oral pimecrolimus in the treatment of moderate to severe chronic plaque‐type psoriasis: a double‐blind, multicentre, randomized, dose‐finding trial (2005) (51)
Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis––a multinational cross-sectional study (2013) (51)
Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study (2016) (51)
Risk of periodontitis in patients with psoriasis and psoriatic arthritis (2017) (50)
Cardiovascular biomarkers in patients with psoriasis (2014) (50)
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis (2017) (50)
Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients. (2001) (50)
Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. (1996) (49)
The German National Program on Psoriasis Health Care 2005–2015: results and experiences (2016) (48)
Cyclosporine in Severe Psoriasis (2001) (48)
The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis (2020) (47)
Genetic susceptibility to keloid disease and transforming growth factor beta 2 polymorphisms. (2002) (46)
Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open‐label study (2012) (46)
Secukinumab is superior to fumaric acid esters in treating patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial (2017) (45)
Genetic susceptibility to keloid disease: Transforming growth factor β receptor gene polymorphisms are not associated with keloid disease (2004) (45)
Interleukin-17 cytokines: Effectors and targets in psoriasis—A breakthrough in understanding and treatment (2019) (45)
Localized Panniculitis and Subsequent Lipoatrophy with Subcutaneous Glatiramer Acetate (Copaxone®) Injection for the Treatment of Multiple Sclerosis (2004) (45)
Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis (2008) (45)
Genetic susceptibility to keloid disease: mutation screening of the TGFbeta3 gene. (2005) (44)
Fumaric acid esters, their place in the treatment of psoriasis (2004) (43)
Highly purified omega‐3‐polyunsaturated fatty acids for topical treatment of psoriasis. Results of a double‐blind, placebo‐controlled multicentre study (1993) (43)
S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 2 – Special patient populations and treatment situations (2018) (43)
Keloid scarring: new treatments ahead. (2009) (43)
Strategies for improving the quality of care in psoriasis with the use of treatment goals – a report on an implementation meeting (2011) (42)
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations (2021) (42)
Topical long‐term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice (2014) (41)
Recommendations for the Long-Term Treatment of Psoriasis with Infliximab: A Dermatology Expert Group Consensus (2008) (39)
The Schnitzler syndrome: Chronic urticaria and monoclonal gammopathy – an autoinflammatory syndrome? (2008) (38)
An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. (2003) (38)
Advances in systemic therapy for psoriasis (2001) (36)
A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64‐week multinational randomized phase IV study in 1790 patients (PSO‐TOP) (2017) (36)
Topology of psoriasis in routine care: results from high‐resolution analysis of 2009 patients (2019) (36)
Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3” (2016) (36)
Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ) (2014) (35)
Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study (2019) (33)
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study (2021) (32)
[S3-Guidelines for the therapy of psoriasis vulgaris]. (2006) (32)
Psoriasis scales contain C5a as the predominant chemotaxin for monocyte‐derived dendritic cells (2001) (32)
A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents. (2020) (32)
Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data (2018) (32)
Effective treatment and improvement of quality of life in patients with scalp psoriasis by topical use of calcipotriol/betamethasone (Xamiol®‐gel): results (2011) (31)
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF 3 IP 2 (2010) (31)
Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling (2017) (31)
Cyclosporine therapy in dermatology (2009) (31)
Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis. (2003) (31)
Expression of dipeptidyl‐peptidase IV (CD26) on CD8+ T cells is significantly decreased in patients with psoriasis vulgaris and atopic dermatitis (2001) (30)
Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman. (2017) (30)
Treatment targeted to cell surface epitopes (2002) (30)
Protection of human skin against jellyfish (Cyanea capillata) stings (1992) (30)
Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials (2019) (30)
Pharmacological targeting of glucose-6-phosphate dehydrogenase in human erythrocytes by Bay 11–7082, parthenolide and dimethyl fumarate (2016) (29)
Impact of comorbidities on the management of psoriasis. (2009) (27)
["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept]. (2009) (27)
[15 years of fumaderm: fumaric acid esters for the systemic treatment of moderately severe and severe psoriasis vulgaris]. (2009) (27)
Strategies to reduce stigma related to visible chronic skin diseases: a systematic review (2019) (26)
CYP1A1 Enzymatic Activity Influences Skin Inflammation Via Regulation of the AHR Pathway (2020) (26)
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study * (2020) (25)
Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies (2005) (24)
Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab (2009) (24)
Differential expression of antimicrobial peptides in psoriasis and psoriatic arthritis as a novel contributory mechanism for skin and joint disease heterogeneity (2016) (23)
A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment (2019) (23)
Small dense LDL cholesterol in human subjects with different chronic inflammatory diseases. (2018) (22)
Effects of psychosocial interventions on patient‐reported outcomes in patients with psoriasis: a systematic review and meta‐analysis (2018) (22)
[Rheumatoid neutrophilic dermatitis--a rare dermatosis in patients with active rheumatoid arthritis]. (1996) (22)
Systemic Treatment with Fumaric Acid Esters in Six Paediatric Patients with Psoriasis in a Psoriasis Centre (2014) (22)
Enhancement of antibacterial superoxide-anion generation in human monocytes by fumaric acid esters (2005) (22)
Downregulation of SMAD2, 4 and 6 mRNA and TGFbeta receptor I mRNA in lesional and non-lesional psoriatic skin. (2009) (22)
[Keloids. A fibroproliferative disorder of unknown etiology]. (2002) (21)
Cyclosporine as maintenance therapy in patients with severe psoriasis. (2013) (21)
Decreased expression of G-protein-coupled receptors GPR43 and GPR109a in psoriatic skin can be restored by topical application of sodium butyrate (2018) (21)
Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study (2015) (21)
Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long‐term psoriasis management (2018) (21)
Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients (2021) (21)
Successful treatment of severe psoriatic arthritis with infliximab in an 11‐year‐old child suffering from linear psoriasis along lines of Blaschko (2007) (20)
Long-Term Treatment with Fumaric Acid Esters in an 11-Year-Old Male Child with Psoriasis (2011) (20)
[The "Antipsoriatic" Skin-Cap contains a non-declared potent corticosteroid]. (1997) (19)
A Phase II, Randomized, Double-Blind Clinical Study Evaluating the Safety, Tolerability, and Efficacy of a Topical Minocycline Foam, FMX103, for the Treatment of Facial Papulopustular Rosacea (2018) (18)
[Psychosocial consequences of psoriasis--an empirical study of disease burden in 3753 affected people]. (2005) (18)
Wnt5a – a potential factor linking psoriasis to metabolic complications (2014) (18)
An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals (2013) (18)
Proliferating tumor cells mimick glucose metabolism of mature human erythrocytes (2019) (18)
[Comorbidity in psoriasis]. (2016) (18)
Vitamin D3 and analogues modulate the expression of CSF-1 and its receptor in human dendritic cells (2002) (17)
Leukocyte adhesion: a suitable target for anti-inflammatory drugs. (2006) (17)
German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations (2021) (17)
Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP) (2014) (17)
Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results (2020) (16)
Translating the WHA resolution in a member state: towards a German programme on ‘Destigmatization’ for individuals with visible chronic skin diseases (2019) (16)
Serum mast cell tryptase is not a useful marker for disease severity in psoriasis or atopic dermatitis (2009) (16)
SERPINB2 and miR‐146a/b are coordinately regulated and act in the suppression of psoriasis‐associated inflammatory responses in keratinocytes (2020) (16)
Oral Health in Patients with Psoriasis-A Prospective Study. (2019) (15)
The use of infliximab in dermatology (2007) (15)
Significant reduction of human monocyte chemotactic response to monocyte‐chemotactic protein 1 in patients with primary and metastatic malignant melanoma (1997) (15)
Roles of the NFκB and glutathione pathways in mature human erythrocytes (2012) (14)
Trifluoperazine-Induced Suicidal Erythrocyte Death and S-Nitrosylation Inhibition, Reversed by the Nitric Oxide Donor Sodium Nitroprusside (2017) (14)
The specific PKC-α inhibitor chelerythrine blunts costunolide-induced eryptosis (2020) (14)
Psychosocial Distress of Patients with Psoriasis: Protocol for an Assessment of Care Needs and the Development of a Supportive Intervention (2018) (14)
Evidence‐based (S3) guideline for the treatment of psoriasis vulgaris – Update: “Therapeutic options” and “Efalizumab” (2010) (14)
Combination therapy in the treatment of psoriasis (2011) (14)
Reaching complete or near‐complete resolution of psoriasis: benefit and risk considerations (2017) (14)
Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes (2015) (14)
Sensitivity of the GEPARD Patient Questionnaire to Identify Psoriatic Arthritis in Patients with Psoriasis in Daily Practice: The GEPARD-Life Study (2016) (13)
[Comorbidities and psoriasis. Impact on clinical practice]. (2012) (13)
Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study * (2020) (12)
Vitamin D(3) and analogues modulate the expression of CSF-1 and its receptor in human dendritic cells. (2002) (12)
Evolution der Biologika in der Entzündungsmedizin – Biosimilars in Gastroenterologie, Rheumatologie und Dermatologie (2014) (12)
Quality of life outcomes in adults with moderate‐to‐severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study (2019) (12)
Lack of efficacy of topical mycophenolic acid in psoriasis vulgaris. (2000) (12)
Dimethyl‐ and monomethylfumarate regulate indoleamine 2,3‐dioxygenase (IDO) activity in human immune cells (2017) (12)
Psoriasis of the tongue. (2009) (12)
Perception and determinants of stigmatization of people with psoriasis in the German population (2020) (12)
Neutrophilic urticarial dermatosis (NUD) in probable adult-onset Still disease responding to anakinra. (2014) (12)
[New information about fumaric acid esters (Fumaderm): results of a workshop of experts]. (2011) (11)
Macrolide immunosuppressants. (1999) (11)
Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method (2021) (11)
Dimethylfumarate induces apoptosis in human mast cells (2013) (11)
Case reports of PML in patients treated for psoriasis. (2013) (11)
German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations (2021) (11)
Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care (2020) (11)
FamilyPso – a new questionnaire to assess the impact of psoriasis on partners and family of patients (2017) (11)
[Report on the symposium "New aspects in the pathogenesis of psoriasis" in Berlin 27 November 1993]. (1994) (10)
Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis (2017) (10)
FRI0460 Secukinumab Shows Significant Efficacy in Nail Psoriasis: Week 32 Results from The Transfigure Study (2016) (9)
Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis (2020) (9)
Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004‐2017 (2021) (9)
Switch of psoriasis therapy from a fumaric acid ester mixture to dimethyl fumarate monotherapy: Results of a prospective study (2019) (9)
Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: extension of the 2PRECISE study. (2020) (9)
[Perception of stigmatization in people with psoriasis-qualitative analysis from the perspective of patients, relatives and healthcare professionals]. (2019) (9)
What is psoriasis? – Perception and assessment of psoriasis among the German population (2018) (8)
Biosimilars in Dermatology – theory becomes reality (2018) (8)
Baseline characteristics of patients with moderate‐to‐severe psoriasis according to previous systemic treatment exposure: the PROSE study population (2020) (8)
Safety Considerations with Cyclosporin and Other Systemic Therapy in the Treatment of Severe Psoriasis (1995) (8)
Effects of calcitriol and its analogues on interaction of MCP-1 and monocyte derived dendritic cells in vitro. (2001) (8)
Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020 (2021) (8)
Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study. (2019) (8)
Phenotypic Differences between Human Blood Monocyte Subpopulations in Psoriasis and Atopic Dermatitis (1997) (8)
Association of sex and systemic therapy treatment outcomes in psoriasis: a two‐country, multicentre, prospective, noninterventional registry study * (2021) (8)
Continued treatment with secukinumab is associated with high retention or regain of response (2019) (7)
A phase 4, randomized, head‐to‐head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate‐to‐severe plaque psoriasis (CHANGE) (2020) (7)
Sex and Age Influence the Associated Risk of Depression in Patients with Psoriasis: A Retrospective Population Study Based on Diagnosis and Drug-Use (2020) (7)
Neutrophils' sexiness is independent of trendy fashion (2017) (7)
Psoriasis is Associated with a High Comedication Burden: A Population Based Register Study (2020) (7)
European consensus statement on phenotypes of pustular psoriasis: ESDR 2016 Annual Meeting Abstract SupplementEuropean Society for Dermatological Research (ESDR) Annual Meeting (2016) (7)
No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis. (2020) (7)
Significant reduction of T-cell chemotaxis to MCP-1 in patients with primary and metastatic melanoma. (1999) (7)
Methotrexate therapy in dermatology (2012) (7)
National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines (2013) (7)
Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care (2020) (6)
Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways (2019) (6)
[Cyclosporins in dermatology]. (2008) (6)
Grover disease and bullous pemphigoid: a clinicopathological study of six cases (2018) (6)
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 52-week results of the ESTEEM 2 Trial (2015) (6)
Oral dimethyl fumarate induces changes within the peripheral neutrophil compartment of patients with psoriasis that are linked with skin improvement * (2021) (6)
Narrowband UVB treatment induces expression of WNT7B, WNT10B and TCF7L2 in psoriasis skin (2019) (6)
Scalp psoriasis (2011) (6)
苏金单抗持续用于治疗银屑病的疗效 (2020) (6)
[Guidelines for cyclosporin therapy in dermatology. Issued by the Consensus Conference on Cyclosporins]. (2001) (6)
Bacterial soft tissue infection in psoriasis despite induction of epidermal antimicrobial peptides (2014) (6)
[Concepts of the mechanisms of action of cyclosporin in psoriasis. A review with guidelines on therapy]. (1993) (6)
Roles of the NFκB and glutathione pathways in mature human erythrocytes (2011) (6)
[Therapy of atopic eczema with calcineurin inhibitors]. (2005) (6)
Long‐term efficacy and safety of brodalumab in moderate‐to‐severe plaque psoriasis: a post hoc pooled analysis of AMAGINE‐2 and ‐3 (2022) (5)
Development of a new method of analysing chemotactic deactivation of human neutrophil granulocytes. (2001) (5)
The effect of tamol on human mast cell chymase and plasmin. (1997) (5)
Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab". (2010) (5)
T-lymphocyte chemotaxis to IL-8 in patients with psoriasis in vitro. (1998) (4)
[Toxic inner ear damage in topical treatment of psoriasis with salicylates]. (1997) (4)
Zonulin may not be a marker of autoimmunity in patients with psoriasis. (2012) (4)
Tannin inhibits histamine release (1999) (4)
Documentation of psoriasis in routine care – expert consensus on a German data set (2021) (4)
The chemotactic activity of T‐lymphocytes in response to interleukin 8 is significantly decreased in patients with psoriasis and atopic dermatitis (1996) (4)
Generalized pustular psoriasis: overview of the status quo and results of a panel discussion (2022) (4)
Online weight‐loss coaching for patients with psoriasis: results of a pilot study (2016) (4)
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis (2021) (4)
[New insights into fumaric acid esters (Fumaderm ®):results of the 2nd Expert Workshops]. (2012) (4)
Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care (2020) (4)
[Methotrexate therapy of inflammatory diseases. Reliable effects and recent developments in rheumatology, pneumology, gastroenterology and dermatology]. (1995) (3)
Dear‐Doctor‐Letter Fumaderm® – What are the facts? (2013) (3)
Expression of low‐density lipoprotein‐related receptors 5 and 6 (LRP5/6) in psoriasis skin (2017) (3)
Ten years of infliximab: its role in dermatology. (2009) (3)
Determinants of costs and benefits in psoriasis routine care: results from a cross‐sectional nationwide study in Germany (2020) (3)
Psoriasis, stress, age and more (2018) (3)
Human erythrocytes, nuclear factor kappaB (NFκB) and hydrogen sulfide (H2S) – from non-genomic to genomic research (2021) (3)
ALIGNed on adherence: subanalysis of adherence in immune‐mediated inflammatory diseases in the DACH region of the global ALIGN study (2018) (3)
Association between nuclear factor of kappa B (NFκB) deficiency and induction of eryptosis in mouse erythrocytes (2020) (3)
[The role of biologics into the management of psoriasis: a consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung]. (2003) (3)
Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis (2019) (3)
Follicular rash during therapy with erlotinib (Tarceva®) (2006) (3)
Simultaneous Onset of Psoriasis Vulgaris in Monozygotic Twins (2001) (3)
[Recommendations when switching therapy from immunosuppressive drugs to dupilumab in patients with atopic dermatitis]. (2020) (2)
Tepilamide Fumarate (PPC-06) Extended Release Tablets in Patients with Moderate-to-Severe Plaque Psoriasis: Safety and Efficacy Results from the Randomized, Double-blind, Placebo-controlled AFFIRM Study. (2022) (2)
Development of a questionnaire to evaluate scratching behavior in patients with psoriasis and atopic dermatitis (2022) (2)
Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals (2021) (2)
Archives of Dermatological Research in the year 2006 (2005) (2)
Comparative efficacy of topical antipsoriatic treatments, systemic treatment and biologics: is severity assessment beyond Psoriasis Area and Severity Index a necessity? (2007) (2)
["Schuppenflechte" or "Psoriasis"? : Wording and awareness of technical terms in the general public]. (2018) (2)
Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate‐to‐severe plaque psoriasis naïve to systemic treatment (2020) (2)
Using the upgrade criteria of the European Psoriasis Consensus is best practice care according to the people‐centred healthcare concept of the World Health Organization (2022) (2)
Bilateral demodicosis of the nipple‐areola complex (2019) (2)
Aldara‐induced skin inflammation in mice: close enough to psoriasis? (2015) (2)
Absolute PASI as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care. (2021) (1)
[Classical topical therapy of psoriasis]. (2006) (1)
Intensive short‐term schema therapy intervention in a patient with psoriasis – case report and clinical management (2020) (1)
EczemaPartner – adapting a questionnaire to assess the impact of atopic dermatitis on partners of patients (2021) (1)
Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial (2022) (1)
Survey regarding the status of senior physicians in German dermatology clinics (2007) (1)
[Therapy of psoriasis vulgaris with efalizumab]. (2006) (1)
Small dense LDL cholesterol is a cardiovascular risk factor in several chronic inflammatory diseases (2016) (1)
26589 Spesolimab, an IL-36R inhibitor, may reduce symptoms of pain in patients with palmoplantar pustulosis – Results from a small pilot study (2021) (1)
Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline – a multivariable regression analysis from the German Psoriasis Registry PsoBest (2022) (1)
Profiles of psychosocial variables and dental status in patients with psoriasis (2020) (1)
[Pruritus in psoriasis : Profile and therapy]. (2016) (1)
Köbner phenomenon in a psoriatic patient under cyclosporin therapy after contusion trauma and local application of hyperaemic ointment. (1993) (1)
A statistical method to convert published response rates into marginal distributions with an example application in psoriasis (2018) (1)
The effect of vitamin D and its analogues calcipotriol and tacalcitol on the differentiation of human monocyte-derived dendritic cells (1998) (1)
Skin colonization with S. aureus can lead to increased NLRP1 inflammasome activation in patients with atopic dermatitis. (2023) (1)
Psoriasis and multiple sclerosis: two diseases, one treatment (2018) (1)
Effectiveness of a structured short intervention against stigmatisation in chronic visible skin diseases: Results of a controlled trial in future educators (2021) (1)
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17 (2022) (1)
Towards a new horizon (2007) (1)
[Psoriasis therapy with biologicals]. (2003) (1)
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study) (2023) (1)
Fumarates for psoriasis: new insights into a small molecule prototype (2014) (1)
060 Integrated safety of ixekizumab in patients with moderate-to-severe psoriasis: results from a pooled analysis of 7 clinical trials (2016) (1)
A Structured Intervention for Medical Students Significantly Improves Awareness of Stigmatisation in Visible Chronic Skin Diseases: A Randomised Controlled Trial (2021) (1)
银屑病严重程度的定义 (2018) (0)
Message from the new Editor-in-Chief (2004) (0)
Contents, Vol. 179, Supplement 1, 1989 (1989) (0)
Measuring well‐being in psoriasis: psychometric properties of the WHO‐5 questionnaire (2022) (0)
Down-regulation of Expression of TGF-β Receptors and SMADs mRNA in Psoriatic Lesional Skin (2004) (0)
32924 Sustained treatment effect of spesolimab over 12 weeks for generalized pustular psoriasis flares; results from the Effisayil 1 study (2022) (0)
Clinical Use and Pharmacological Profile of Fumaric Acid Esters (2007) (0)
Abstract 868: Prevalence, Underdiagnosis, and Undertreatment of Cardiovascular Risk Factors in Patients With Moderate-to-Severe Psoriasis (2009) (0)
Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis (2022) (0)
25991 Application of the statistical method to convert published PASI 50/75/90/100 into absolute PASI response rate in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab based on data from two pivotal phase 3 studies (reSURFACE 1/2) (2021) (0)
[Skin blackish hyperpigmentation in 3 patients]. (2002) (0)
Announcement (1995) (0)
The efficacy of secukinumab with continued use in the treatment of psoriasis (2020) (0)
Role of Nicotinuric acid in metabolic inflammation and type 2 diabetes (2021) (0)
比较生物制剂依奇珠单抗与其他两种治疗银屑病的药物富马酸酯和甲氨蝶呤的试验 (2020) (0)
‘Wonder Drugs’ for Psoriasis (2001) (0)
764 miR-146a and miR-146b regulate members of the IL-1β family in human primary keratinocytes (2018) (0)
Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial (2021) (0)
[Systemic treatment of moderate/severe hidradenitis suppurativa]. (2021) (0)
[Self-help groups in dermatology--a survey in Germany]. (2013) (0)
FRI0198 Multi-Country, Cross-Sectional Study to Determine Patient-Specific and General Beliefs towards Medication and their Treatment Adherence to Selected Systemic Therapies in 6 Chronic Immune-Mediated Inflammatory Diseases (ALIGN) (2014) (0)
Anarcho reloaded (2017) (0)
Keloid Scarring: New Treatments Ahead (2009) (0)
ActiPso: de ﬁ nition of activity types for psoriatic disease: A novel marker for an advanced disease classi ﬁ cation (2021) (0)
319 S. aureus can induce NLRP1 inflammasome activation in patients with atopic dermatitis (2022) (0)
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial (2022) (0)
Rapid and sustained improvements in GPPGA scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study. (2023) (0)
Measuring patient‐relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10‐item short form (2022) (0)
SARS-CoV-2 vaccination status and adverse events among patients with psoriasis - data from the German Registries PsoBest and CoronaBest. (2023) (0)
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. (2023) (0)
478 Psoriasis and its impact on close relatives/partners of patients – a single-center cross-sectional questionnaire study (2023) (0)
ICG-based Optical Imaging Suggests Subclinical Involvement of Asymptomatic Joints in Psoriatic Arthritis but not in Arthrosis (2014) (0)
Symptom Experience and Content Validity of the Psoriasis Symptom Scale (PSS) in Patients with Generalized Pustular Psoriasis (GPP) (2022) (0)
Application of the Statistical Method to Convert Published PASI 50/75/90/100 into Absolute PASI Response Rate in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab Based on Data from the Two Pivotal Phase 3 Studies reSURFACE 1 and reSURFACE 2 (2022) (0)
578 Expression of the G protein-coupled receptors GPR109A and GPR43 is downregulated in psoriatic skin (2017) (0)
[Large surface yellowish plaque in the area of burn scars]. (2001) (0)
[Learning from each other, treating together]. (2021) (0)
AB0952 Characterization of patients with psoriatic arthritis in dermatologic and rheumatologic care: an analysis of two disease registries (2022) (0)
Topical Minocycline Foam (FMX-103) for the Treatment of Moderate-to-Severe Rosacea: Results of a Phase 2, Randomized, Double-Blind, Multicenter Clinical Study (2017) (0)
Chemokine and chemokine receptor mRNA expression is differentially regulated during IL-4 and GM-CSF-dependent differentiation of human monocyte-derived dendritic cells (1998) (0)
[Do vitamin D3 and analogs have an antipsoriatic effect?]. (1999) (0)
Papulonodular tattoo lesions as a clinical sign of systemic sarcoidosis (2022) (0)
ORAL DIMETHYL FUMARATE TARGETS HCA2-EXPRESSING SKIN CELLS IN THE IMIQUIMOD MOUSE MODEL. (2022) (0)
Absolute Psoriasis Area and Severity Index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care (2021) (0)
Tagesnotizen (2016) (0)
Management of refractory plaque psoriasis (2002) (0)
Erratum (1995) (0)
Psoriasis and cardiometabolic risk: independent association but distinct genetic architectures (2015) (0)
[Therapy of psoriasis-arthritis and psoriasis vulgaris with infliximab]. (2006) (0)
ILDS Newsletter No. 32 (2014) (0)
[Significance of T-lymphocytes for pathogenesis of psoriasis--interdisciplinary aspects. Report of a Workshop 22 November 1996 in Heiligenstedten Castle]. (1997) (0)
33130 Effect of tildrakizumab on work/study-related productivity: Pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials (2022) (0)
Management der Psoriasis (2021) (0)
7.1 Psoriasis vulgaris (2002) (0)
390 SERPINB2 is regulated by the NF-κB pathway and miR-146a in human primary keratinocytes and psoriasis (2017) (0)
Supplementary Material for: Sensitivity of the GEPARD Patient Questionnaire to Identify Psoriatic Arthritis in Patients with Psoriasis in Daily Practice: The GEPARD-Life Study (2016) (0)
Newsletter No. 10/2010 (2010) (0)
27383 Bimekizumab response maintenance up to 1 year in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials (2021) (0)
Ultraviolet treatment and mastocytosis: A survey of 39 patients (2002) (0)
[Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept]. (2005) (0)
[Report of the 9th Psoriasis Specialty Congress, Bad Bentheim, 5 April 2003]. (2003) (0)
[Differential diagnostic spectrum of psoriasis vs. psoriatic arthritis in skin and joints]. (2017) (0)
13065 More moderate levels of disease severity at baseline related to achievement of treatment targets with apremilast: Results from a pooled analysis (2020) (0)
[Nephrotoxic action of fumaric acid]. (2000) (0)
Ustekinumab and Marked Clinical Responses in Patients with Moderate to Severe Psoriasis (2010) (0)
Der Thermomix (2019) (0)
[Erythema (chronicum) migrans. The clinical variability of the earliest manifestation of Lyme borreliosis]. (1996) (0)
A trial to compare the biologic drug ixekizumab with two other treatments for psoraisis, fumaric acid esters and methotrexate (2020) (0)
291 Improvements in GPPGA score in patients experiencing a generalized pustular psoriasis (GPP) flare: Effisayil 1 study results (2022) (0)
Reaching Treatment Goals in Psoriasis with Conventional Systemic Drugs: How Long Are We Willing to Wait? (2021) (0)
New insights into the mode of action of the antipsoriatic drug dimethylfumarate: P15 (2008) (0)
'Wonder drugs' for psoriasis a never ending story. (2001) (0)
Election of Professor Enno Christophers as “Honorary Editor” (2004) (0)
Differentiation between arthrosis (Art) and psoriatic arthritis (PA) using fluorescence optical imaging (2014) (0)
7.3 Nagelpsoriasis (2002) (0)
PPC 06 ( Tepilamide Fumarate), a novel fumaric acid ester, is efficacious in treating plaque psoriasis: Results from a phase 2b randomized controlled trial (2019) (0)
Highly purified omega-3-polyunsaturated fatty acids for topical treatment in psoriasis — Results of a double-blind, placebo-controlled multicentre study (1993) (0)
Definition of psoriasis severity (2018) (0)
[Guidelines for therapy with fumaric acid ester]. (2001) (0)
16234 Online case-based education improves dermatologists’ knowledge and confidence regarding psoriasis treatment selection (2020) (0)
ActiPso: definition of activity types for psoriatic disease: A novel marker for an advanced disease classification (2021) (0)
Subgroup Analyses by European Country-Specific Reimbursement Requirements Confirm Efficacy for Ixekizumab in Psoriasis. (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ulrich Mrowietz?

Ulrich Mrowietz is affiliated with the following schools:

University of Cologne
Kiel University

Ulrich Mrowietz's Academic­Influence.com Rankings

Why Is Ulrich Mrowietz Influential?

Ulrich Mrowietz's Published Works

Published Works

What Schools Are Affiliated With Ulrich Mrowietz?

Ulrich Mrowietz's AcademicInfluence.com Rankings